论文部分内容阅读
一般认为生物疗法是癌症的第四种治疗方法。将原形淋巴细胞取出与IL-2共培养,不仅淋巴细胞的数量增加,而且产生淋巴因子活化的杀伤细胞(LAK),LAK细胞具有更强的杀伤肿瘤细胞的能力。1986年从肿瘤中分离出一组细胞称为肿瘤浸润淋巴细胞(TIL_s),TIL_s已有激活的杀伤功能,其诱导肿瘤缩小作用比LAK细胞强50～100倍。用LAK/TIL细胞和IL-2对癌症患者进行的生物疗法仅在采取十分复杂的给药方案时,才使少数人的免疫应答能力提高。NCI一委员会最近临时批准将肿瘤坏死因子(TNF)或IL-2等的基因插入到从患者身上分离出的肿瘤细胞中,然后再将已改变的
Biotherapy is generally considered the fourth treatment of cancer. Co-culture of prototypic lymphocytes with IL-2 not only increased the number of lymphocytes, but also produced lymphokine-activated killer cells (LAK). LAK cells have a greater ability to kill tumor cells. In 1986, a group of cells was isolated from tumors called tumor-infiltrating lymphocytes (TIL_s). TIL_s has activated killing function, and its induction of tumor shrinkage is 50-100 times stronger than that of LAK cells. Biological therapy of cancer patients with LAK/TIL cells and IL-2 only increased the immune response of a few people when very complicated dosing regimens were used. The NCI Committee has recently approved the insertion of genes such as tumor necrosis factor (TNF) or IL-2 into tumor cells isolated from patients, and then changed